Hypertensive emergencies, characterized by acute, severe elevations in blood pressure associated with end-organ damage, present unique challenges to clinicians. Early recognition and appropriate management are crucial to mitigate the risk of adverse outcomes.
Accurate diagnosis begins with a comprehensive patient history and physical examination. Blood pressure should be measured in both arms, and the higher reading should be used for diagnosis. Clinicians should look for signs of end-organ damage such as altered mental status, chest pain, shortness of breath or focal neurological deficits. Lab tests, including complete blood count, serum creatinine, and urinalysis, can provide supporting evidence of organ damage.
Management of hypertensive emergencies involves rapid but controlled reduction of blood pressure. Intravenous antihypertensive agents are preferred due to their rapid onset and titratability. Agents such as sodium nitroprusside, labetalol, and nicardipine are commonly used. The initial goal is to reduce mean arterial pressure by no more than 25% within the first hour, then to 160/100-110 mmHg over the next 2-6 hours.
Once the acute phase is controlled, clinicians should focus on long-term management. This includes lifestyle modifications and oral antihypertensive medications. The choice of drug should be individualized based on patient characteristics such as age, comorbidities, and potential drug-drug interactions.
Hypertensive emergencies require prompt recognition and aggressive management to prevent serious complications. Clinicians should maintain a high index of suspicion in patients presenting with severe hypertension and signs of end-organ damage. Careful selection of antihypertensive agents and diligent follow-up are key to achieving optimal patient outcomes.
1.
Prostate cancer death risk is higher in late teens and early 20s weight gain.
2.
Bayer is transforming pharmaceutical research into women's health
3.
Biomarker panel offers hope for early pancreatic cancer detection
4.
A small rise in cancer was observed following the 1986 Chernobyl accident.
5.
Added Plinabulin Boosts OS as Later-Line Treatment for EGFR Wild-Type NSCLC
1.
Beyond the Brain Fog: The Complex Neurological Challenges and Therapeutic Advances
2.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
3.
Immune Microenvironment Biomarkers for Early Tumor Evolution
4.
Transformative Methods in Oncology and Quality Improvement
5.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation